文献速递心脑血管急症重症综合管理与镇静镇痛儿科与产科急症

基孔肯雅热的神经系统并发症谱

The Range of Neurological Complications in Chikungunya Fever.
PubMed 文献 · Neurocrit Care · 2017-01-01
一句话结论系统综述显示基孔肯雅热神经系统并发症以脑炎、视神经病变、神经视网膜炎和吉兰-巴雷综合征为主,直接病毒型多见于婴儿和老年人,自身免疫型多见于20岁以上患者且潜伏期更长、预后更好。

该研究为病例报告加系统综述,按既定指南检索并纳入36项研究共130例基孔肯雅热神经系统并发症病例,用5步临床诊断算法分为A、B、C三级,仅A、B级进一步分析。患者年龄呈双峰分布,均值49岁,第二峰在婴儿;50%病例年龄<45岁且无报告合并症。常见诊断包括脑炎、视神经病变、神经视网膜炎和吉兰-巴雷综合征,直接病毒机制相关神经病变在婴儿和老年患者中达峰且并发症和神经后遗症更频繁,自身免疫介导病变主要见于20岁以上患者、潜伏期趋于更长且结局更好。来自印度和留尼汪的病例地理亚组分析显示表型趋势不同(留尼汪88%为直接病毒型 vs 印度81%为自身免疫型)。

要点

  • 130例基孔肯雅热神经系统并发症中,仅9例为A级(可能神经基孔肯雅热诊断)、55例B级(合理)、51例C级(有争议),15例更可能为其他诊断。
  • 常见神经系统诊断为脑炎、视神经病变、神经视网膜炎和吉兰-巴雷综合征。
  • 直接病毒机制相关神经病变在婴儿和老年患者中出现高峰,且这些人群并发症和神经后遗症更频繁。
  • 自身免疫介导病变主要见于20岁以上患者,倾向于潜伏期更长、结局更好。
  • 地理亚组分析显示留尼汪病例88%为直接病毒型,印度病例81%为自身免疫型。

适用人群与场景

  • 基孔肯雅热患者中出现神经系统表现的病例,年龄分布呈双峰,均值49岁,第二峰在婴儿;50%病例年龄<45岁且无报告合并症。

诊断标准与关键阈值

  • 采用5步临床诊断算法将病例分为A-C级,A级代表最高质量(神经基孔肯雅热 probable),B级为合理(plausible),C级为有争议(disputable);仅A和B级病例纳入进一步分析。

研究设计与关键结果

  • 系统综述纳入36项研究共130例病例:9例A级、55例B级、51例C级,15例更可能为其他诊断。
  • 患者年龄分布双峰,均值49岁,第二峰在婴儿;50%病例年龄<45岁且无报告合并症。
  • 常见诊断:脑炎、视神经病变、神经视网膜炎、吉兰-巴雷综合征。
  • 直接病毒机制相关神经病变在婴儿和老年患者中出现高峰,且这些人群并发症和神经后遗症更频繁。
  • 自身免疫介导病变主要见于20岁以上患者,倾向于潜伏期更长、结局更好。
  • 地理亚组:留尼汪病例88%为直接病毒型 vs 印度病例81%为自身免疫型。

证据类型、等级与局限

  • 证据类型:病例报告加系统综述,遵循既定指南;采用5步临床诊断算法进行质量分级。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,直接病毒型神经基孔肯雅热似乎尤其发生于婴儿和老年患者,而自身免疫型也须考虑于中年、既往健康患者,尤其是无症状间隔之后。
  • 作者认为,该知识有助于识别未来的神经基孔肯雅热病例并改善结局,尤其是自身免疫介导的病变。
  • 作者认为,基孔肯雅病毒基因可能在决定神经发病机制病程中起关键作用,进一步研究可能具有诊断意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Chikungunya fever is a globally spreading mosquito-borne disease that shows an unexpected neurovirulence. Even though the neurological complications have been a major cause of intensive care unit admission and death, to date, there is no systematic analysis of their spectrum available.

OBJECTIVE: To review evidence of neurological manifestations in Chikungunya fever and map their epidemiology, clinical spectrum, pathomechanisms, diagnostics, therapies and outcomes.

METHODS: Case report and systematic review of the literature followed established guidelines. All cases found were assessed using a 5-step clinical diagnostic algorithm assigning categories A-C, category A representing the highest level of quality. Only A and B cases were considered for further analysis. After general analysis, cases were clustered according to geospatial criteria for subgroup analysis.

RESULTS: Thirty-six of 1196 studies were included, yielding 130 cases. Nine were ranked as category A (diagnosis of Neuro-Chikungunya probable), 55 as B (plausible), and 51 as C (disputable). In 15 cases, alternative diagnoses were more likely. Patient age distribution was bimodal with a mean of 49 years and a second peak in infants. Fifty percent of the cases occurred in patients <45 years with no reported comorbidity. Frequent diagnoses were encephalitis, optic neuropathy, neuroretinitis, and Guillain-Barré syndrome. Neurologic conditions showing characteristics of a direct viral pathomechanism showed a peak in infants and a second one in elder patients, and complications and neurologic sequelae were more frequent in these groups. Autoimmune-mediated conditions appeared mainly in patients over 20 years and tended to show longer latencies and better outcomes. Geospatial subgrouping of case reports from either India or Réunion revealed diverging phenotypic trends (Réunion: 88% direct viral vs. India: 81% autoimmune).

CONCLUSIONS: Direct viral forms of Neuro-Chikungunya seem to occur particularly in infants and elderly patients, while autoimmune forms have to be also considered in middle-aged, previously healthy patients, especially after an asymptomatic interval. This knowledge will help to identify future Neuro-Chikungunya cases and to improve outcome especially in autoimmune-mediated conditions. The genetics of Chikungunya virus might play a key role in determining the course of neuropathogenesis. With further research, this could prove diagnostically significant.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Cerny T, Schwarz M, Schwarz U, et al. The Range of Neurological Complications in Chikungunya Fever. Neurocrit Care. 2017. PMID: 28741102. doi:10.1007/s12028-017-0413-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。